New protocol generated glucose-responsive SC-islets from eight hPSC lines tested, demonstrating potential for autologous applications.

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...

Researchers identified GSK3α as a key checkpoint controlling stem cell identity across multiple cell types. Inhibiting it ...

Liver fibrosis represents a serious worldwide health issue with a prevalence of around 5% in general populations.1 The most ...

Why does the same genetic mutation cause a severe brain malformation in some patients but not in others? Researchers from the ...

STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...

STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...

Creating artificial systems that mimic the functioning of cells is one of the goals of what is known as synthetic biology.

Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...

Aortic aneurysms are characterized by abnormal enlargement of the aorta, the primary artery responsible for carrying blood from the heart. Rupture often leads to sudden death, and currently, no ...